Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ET

Company Participants

Bill Slattery - VP, IR
Pravin Dugel - Executive Chairman, President, CEO
Steve Meyers - Chief Commercial Officer

Conference Call Participants

Tazeen Ahmad - Bank of America
Biren Amin - Piper Sandler
Tara Bancroft - TD Cowen
Kelly Shi - Jefferies
Sean McCutcheon - Raymond James
Yi Chen - H.C. Wainwright
Greg Harrison - Scotiabank

Operator

Good morning, and welcome to the Ocular Therapeutix Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the prepared remarks, we will conduct a question-and-answer session. [Operator Instructions] As a reminder, this conference call is being recorded and will be available for replay on the Investor Relations section of the Ocular Therapeutix website.

I would now like to turn the call over to Ocular's Vice President of Investor Relations, Bill Slattery Jr. Please go ahead, Mr. Slattery.

Bill Slattery

Good morning, everyone, and thank you for joining us today. Earlier this morning, we issued a press release outlining our financial results and business updates for the third quarter 2024. Mindful of everyone's time, Ocular's Executive Chairman, President, and CEO, Dr. Pravin Dugel, will briefly provide a summary of recent business highlights, so we can quickly get to your questions. Joining Dr. Dugel for the Q&A portion of the call will be Donald Notman, Chief Financial Officer and Chief Operating Officer; Sanjay Nayak, Chief Strategy Officer; and Steve Meyers, Chief Commercial Officer.

We refer everyone to this morning's press release and our Form 10-Q for a comprehensive update of third quarter financial and business results. During today's call, certain statements we will be making constitute forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially as a result of variety of factors including risks and uncertainties identified in the Risk Factors section of our annual report on Form 10-K and our other SEC filings.

With that, I'd like to hand the call over to Dr. Pravin Dugel to review our recent updates. Pravin?

Pravin Dugel

Thank you, Bill, and thank you to everyone for joining us today. When I joined Ocular, our number one priority was bringing AXPAXLI to market for wet age-related macular degeneration. Wet AMD affects about 1.65 million people in the United States, which translates to approximately one in every 160 adults. That means many of us are likely to know someone who is affected by this disease, and it reminds us that this market is large and underserved with up to 40% of patients discontinuing treatment within the first year alone.